Note 5 — Goodwill and Other Intangible Assets

As part of the Company’s annual impairment review as of December 31, 2011, a $19,432,700 goodwill impairment charge was recorded within the Company’s Pharmaceutical Manufacturing — China reportable segment due to lower than expected revenue and operating income growth. The Company estimated the fair value utilizing a discounted cash flow model.

As part of the Company’s annual impairment review as of December 31, 2010, a $558,200 goodwill impairment charge was recorded within the Company’s Cell Therapy — United States reportable segment due to lower than expected revenue and operating income growth of its adult stem cell banking area. The Company estimated the fair value utilizing a discounted cash flow model.

The changes in the carrying amount of goodwill, by reportable segment during 2011 and 2010 were as follows (in thousands):


	Cell Therapy — United States			Pharmaceutical Manufacturing — China			Total
Balance as of December 31, 2009	$	558.2		$	26,076.4		$	26,634.6
Impairment		(558.2	)		—			(558.2	)
Foreign currency exchange rate changes		—			925.6			925.6
Balance as of December 31, 2010		—			27,002.0			27,002.0
Acquisitions*		11,117.8			—			11,117.8
Impairment					(19,432.7	)		(19,432.7	)
Foreign currency exchange rate changes		—			926.4			926.4
Balance as of December 31, 2011	$	11,117.8		$	8,495.7		$	19,613.5

Approximately $7,013,300 associated with the PCT Merger, and $4,104,500 associated with Amorcyte merger

As of December 31, 2011 and 2010, the Company’s intangible assets and related accumulated amortization consisted of the following (in thousands):



			December 31, 2011							December 31, 2010
	Useful Life		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list		10 Years	$	19,373.8	$	(4,076.1	)	$	15,297.7	$	17,740.0	$	(2,069.7	)	$	15,670.3
Manufacturing technology		10 Years		8,779.9		(1,368.9	)		7,411.0		4,220.6		(492.4	)		3,728.2
Tradename		10 Years		1,819.0		(296.9	)		1,522.1		983.9		(114.7	)		869.2
In process R&D		Indefinite		11,190.4		—			11,190.4		2,219.6		—			2,219.6
Standard operating procedures		10 Years		1,104.9		(239.4	)		865.5		1,066.8		(124.5	)		942.3
Lease rights		2 Years		846.4		(846.4	)		—		817.2		(476.7	)		340.5
VSEL patent rights		19 Years		669.0		(140.8	)		528.2		669.0		(105.6	)		563.4
Patents		8 Years		204.3		(86.8	)		117.5		164.3		(31.2	)		133.1
Total Intangible Assets			$	43,987.7	$	(7,055.3	)	$	36,932.4	$	27,881.4	$	(3,414.8	)	$	24,466.6

In 2011, Erye commenced sales of two products that were previously accounted for as In Process R&D which has resulted in a reclassification of approximately $505,500 from In Process R&D to Manufacturing Technology. Certain of the Company’s intangible assets are recorded on the books of wholly owned or partially owned subsidiaries and affiliates in China, and denominated in RMB. As a result, the balance reported fluctuates based upon the changes in exchange rates.

In connection with the acquisition of PCT, the following intangible assets were acquired (in thousands):


Customer list	$	1,000.0
Manufacturing technology		3,900.0
Tradename		800.0
	$	5,700.0

In connection with the acquisition of Amorcyte, an In Process R&D intangible asset of $9,400,000 was recorded.

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):


	Years Ended December 31,
	2011		2010
Cost of revenue	$	1,305.3	$	912.5
Research and development		55.3		35.2
Selling, general and administrative		2,078.2		1,842.0
Total	$	3,438.8	$	2,789.7

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follows (in thousands):


2012	$	3,168.5
2013		3,168.5
2014		3,168.5
2015		3,168.5
2016		3,158.3
Thereafter		21,100.1
	$	36,932.4

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details